
New diagnostic criteria for MS (Submitted for EACCME® accreditation)
About this e-learning
Welcome to our e-learning on “New diagnostic criteria for MS”.
This e-learning module explores the 2024 revision of the McDonald diagnostic criteria for Multiple Sclerosis (MS), providing a practical and clinically grounded overview for healthcare professionals. Designed for neurologists and MS specialists, it presents the most recent evidence and consensus updates aimed at improving diagnostic accuracy—particularly in early and complex cases. The course covers key advancements such as the inclusion of the optic nerve as a fifth anatomical site in dissemination in space (DIS), the integration of advanced imaging biomarkers like the Central Vein Sign (CVS) and Paramagnetic Rim Lesions (PRLs), and the evolving role of kappa free light chains (k-FLCs) as a biomarker alternative to oligoclonal bands (OCBs). Special diagnostic considerations in older adults, patients with vascular comorbidities, and paediatric populations are also addressed, helping clinicians apply the criteria more confidently across diverse patient groups.
Certificate
Participants will receive a ParadigMS Certificate upon completion. Once accreditation is granted, an official EACCME® Certificate will also be available.
Learning objectives
By the end of this e-learning, participants will be able to:
- Explain the key updates introduced in the 2024 McDonald diagnostic criteria for MS, including the rationale behind the revisions.
- Identify the optic nerve as a fifth topographical location for demonstrating dissemination in space (DIS), and understand how MRI, OCT, and VEP can be used to detect relevant lesions.
- Evaluate the role of new imaging biomarkers, such as the Central Vein Sign (CVS) and Paramagnetic Rim Lesions (PRLs), in increasing diagnostic specificity.
- Apply the updated criteria across different patient populations, including older adults with vascular risk factors, children with demyelinating events, and patients with radiologically isolated syndrome (RIS).
- Differentiate between MS and its common mimics, using updated diagnostic tools and clinical strategies.
- Assess the use of cerebrospinal fluid (CSF) biomarkers, especially the role of kappa free light chains (k-FLCs) as an alternative to oligoclonal bands (OCBs).